Why the study?
Do therapeutic interventions targeting TxA2 receptors and TxA2 synthase improve outcomes in cardiovascular and renal diseases?
Do therapeutic interventions targeting TxA2 receptors and TxA2 synthase improve outcomes in cardiovascular and renal diseases?
Interventions targeting the TxA2 pathway, such as dual TP-receptor antagonists and TS inhibitors, offer potential novel treatments for arterial thrombosis, atherogenesis, and renal proteinuria, particularly in patients with poor response to standard antiplatelet therapy.
Hypothesis-generating for TxA2 pathway inhibition; prospective trials needed before clinical adoption in thrombosis or renal disease.
The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria. Particular emphasis is laid on therapeutic interventions targeting the TxA2 (TP) receptors and TxA2 synthase (TS), including dual TP-receptor antagonists and TS inhibitors. Their significant inhibitory efficacies on arterial thrombogenesis, atherogenesis, restenosis after stent placement, vasoconstriction and proteinuria indicate novel and improved treatments for cardiovascular and selected renal diseases. New therapeutic interventions of the TxA2 pathway may also be beneficial for patients with poor biological antiplatelet drug response, for example, to aspirin and/or clopidogrel. These new TP/TS agents offer novel improved treatments to efficiently and simultaneously interfere with thrombogenesis and atherogenesis, and to enlarge the existing panel of platelet inhibitors for efficient prophylaxis and treatment of arterial thrombosis and renal proteinuria.
No takes yet. Share an insight, caveat, or question.
Sakaríassen et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: